Loading...
•
Dec 31, 2019
Adicet Bio Q4 2019 Earnings Report
resTORbio reported financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.
Key Takeaways
resTORbio reported a net loss of $28.9 million for the fourth quarter of 2019, with R&D expenses at $26.1 million and G&A expenses at $3.3 million. The company's cash, cash equivalents, and marketable securities totaled $91.5 million as of December 31, 2019. The company is focusing on its Phase 1b/2a trial of RTB101 in Parkinson's disease and exploring strategic alternatives to enhance shareholder value.
Phase 1b/2a trial of RTB101 alone and in combination with sirolimus in Parkinson’s disease showed that the first 3 dosing regimens were well tolerated and RTB101 300 mg once weekly was observed to cross the blood brain barrier.
R&D expenses were $26.1 million for the three months ended December 31, 2019.
G&A expenses were $3.3 million for the three months ended December 31, 2019.
Net loss was $28.9 million, or $0.79 per share, for the three months ended December 31, 2019.
Forward Guidance
resTORbio expects that current cash, cash equivalents and marketable securities as of December 31, 2019 will be sufficient to fund its operating expenses at least into 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...